GO
| HSI1 | 25,511.10 | 0.00 | -- |
| HSCEI1 | 8,445.37 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-08-25 18:20:45 INNOVENT BIO (01801.HK) announced its interim results for the six months ended June 2026. Total revenue mounted 44.8% YoY to RMB8.618 billion. Profit for the period climbed 50.2% YoY to RMB1.253 billion. EPS was RMB0.73. Non-IFRS profit during the period grew 40.5% to RMB1.703 billion. During the period, gross profit lifted 43% to RMB7.32 billion, while gross margin edged down to 85% from 86%. Non-IFRS EBITDA rose 47.1% to RMB2.08 billion. ~ AASTOCKS Financial News Website: www.aastocks.com | |